CDC34抑制了巨细胞的细胞活动,并预测癌症中对免疫检查点抑制剂的反应不佳
Xiao-Liang Jie1, Jia-Cong Wei2, Di Wang3
1State Key Laboratory of Molecular Oncology & Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Jiangxi Key Laboratory of Oncology (2024SSY06041), Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, 330029, Jiangxi, China.
细胞分裂周期34 (CDC34) 通过稳定CD47促进癌症免疫逃避,阻碍巨细胞灭菌. 抑制CDC34可能会克服对免疫治疗的耐药性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 细胞分裂周期34 (CDC34) 是一种E2无素结合酶,参与蛋白质降解和稳定.
- CDC34已涉及促进癌症发生,包括稳定表皮生长因子受体.
研究的目的:
- 调查CDC34在各种癌症类型的癌症进展和免疫逃避中的作用.
- 探索CDC34作为增强免疫疗法疗效的潜在治疗点.
主要方法:
- 癌症基因组图谱 (TCGA) 数据集的泛癌症分析.
- 单细胞RNA测序分析以评估CDC34在巨细胞活动中的作用.
- 用于评估CDC34抑制和与抗PD-L1.1联合治疗的小鼠模型.
- 对患者样本进行分析,以确定CDC34,CD47,T细胞透和免疫治疗反应之间的相关性.
主要成果:
- 在乳腺癌中观察到高的CDC34表达,与患者的不良结果有关.
- CDC34通过稳定缺氧诱导因子1α (HIF1α) 和提高癌细胞中CD47的调节,对巨细胞细胞形成产生负面影响.
- 在小鼠中,CDC34抑制降低了瘤生长,并与抗PD-L1疗法产生协同作用.
- 疾病预防控制中心34的过度表达与CD47相关,并减少了患者的CD8+T细胞透.
- 不对免疫治疗有反应的患者表现出较高的CDC34水平和较低的CD8+T细胞透.
结论:
- CDC34通过促进CD47介导的细胞酶耐药性,在癌症免疫逃避中发挥着至关重要的作用.
- 针对CDC34可能是一个可行的策略,以改善免疫检查点抑制剂耐药的患者的结果.
- 在临床前模型中,CDC34和PD-L1的联合向表明了治疗潜力.
更多相关视频
08:41Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
Published on: June 7, 2017
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
相关概念视频
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Abnormal Proliferation
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
